ICER to assess synthetic psilocybin therapy COMP360 for treatment-resistant depression, with public comments open through November 10, 2026

The Institute for Clinical and Economic Review will assess the comparative clinical effectiveness and value of synthetic psilocybin, also called COMP360 and developed by COMPASS Pathways, for treatment-resistant depression. The assessment will be discussed at a New England Comparative Effectiveness Public Advisory Council meeting in May 2027, where an independent evidence review panel will deliberate and vote on the evidence presented in ICER's report. ICER has published a Draft Scoping Document after five weeks of outreach to the manufacturer, patient groups, and clinical experts. Stakeholders may submit comments and suggested refinements by 5 PM ET on November 10, 2026, while submissions on low-value care practices may help inform recommendations on reducing waste and preserving resources. A revised scoping document is expected around November 18, 2026.